Slam Bio is a biotech company developing a platform of very promising first-in-class human bispecific monoclonal antibody and antibody-drug conjugates (ADCs) targeting the most challenging blood cancers. SLAM Bio’s lead assets demonstrate a profound activity against these cancers in preclinical models.
Our mission is to pioneer paradigm-changing therapies that offer a beacon of hope to patients, ushering in a new era of breakthroughs in the fight against cancer.
Our seasoned and proven leadership team—led by CEO Steve Potts; Chairman and Co-Founder, Rick Heinick; SAB Chair and Co-Founder, Dr. Steven Rosen; along with an experienced oncology team—has been involved in multiple successful drug development programs and exits. The team includes scientists, clinicians and business professionals, all who bring unique skills and perspectives.
Innovation is at the heart of what we do at SLAM Bio.
Our primary indication is acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Our secondary indications are a broad spectrum of both T and B cell Non-Hodgkin lymphomas including cutaneous and peripheral T-cell lymphomas and both diffuse large B-cell and follicular lymphomas .
Our novel humanized monoclonal antibodies target SLAM F5 (CD84) a cell surface adhesion molecule which is part of the signaling lymphocytic activation molecule (SLAM) family of receptors. The lead antibodies target SLAMF5 (CD84) with high affinity, compelling efficacy, and restricted normal tissue expression.
We have a broad and fresh IP portfolio of more than 17 antibodies. Our Phase I clinical trials will be initiated in the first half of 2026 for hematologic cancers.
We have partnered with two leading cancer research institutions, City of Hope and the Weizmann Institute, to develop innovative solutions with the potential to extend and enhance the lives of people with cancer.
THOUSAND OAKS, CA – January 3, 2024. SLAM BioTherapeutics, Inc., a promising biotechnology company, dedicated to novel oncology and autoimmune therapies, announces a seed round of over $8 Million to advance its portfolio of antibodies. The company’s suite of antibodies targets a novel cell surface receptor expressed in the tumor microenvironment.
Leading the investment was Schwartz Capital Group. The funds raised will support SLAM Bio’s pre-clinical development efforts and facilitate Investigational New Drug (IND) enabling studies for its lead asset.
SLAM Bio was co-founded by distinguished cancer researcher Dr. Steven Rosen, Emeritus Director of Beckman Research Institute of City of Hope, veteran biotech executive Rick Heinick and Prof. Idit Shachar from the Weizmann Institute. The company is targeting the signaling lymphocytic activation molecule (SLAM) family of receptors, which modulate myeloid-derived suppressor cells (MDSCs), B regulatory and T regulatory cells and associated activation of cytotoxic T and Natural Killer cells.
Rick Heinick, Chairman of SLAM Bio, commented, “These advances are a textbook case of how new discoveries from a seemingly well- explored area of bioscience can lead to breakthrough therapies for patients with hematologic and solid tumor cancers. This team has demonstrated remarkable capability to execute, and we are excited about the future here.”
“SLAM Bio’s portfolio of novel antibodies has demonstrated promising preclinical results with the potential to curb the growth and spread of a broad spectrum of cancers. We are excited to be a part of this important mission,” remarked Ted Schwartz, founder of Schwartz Capital Group and a lymphoma survivor.
About SLAM BioTherapeutics
Slam Bio is a preclinical stage biotech company developing antibody therapies for cancer and autoimmune diseases. SLAM Bio’s lead assets have first-in-class potential and have demonstrated a profound effect on the tumor micro-environment in preclinical models.
More information available at www.slambio.com.
Visit us on social media:
LinkedIn
Please send us a message for more information.
3148 Versaille Court, Thousand Oaks, California 91362, United States